Is Ripretinib domestically produced or imported?

Ripretinib is a novel switch-controlled TKI that inhibits KIT and PDGFRA kinase signaling through a dual mechanism of action, inhibiting many of the most common primary and secondary KIT and PDGFRA mutants associated with the progression of gastrointestinal stromal tumor GISTs. The superior efficacy of rapitinib relative to placebo in the context of best supportive care, as well as its favorable safety profile and improvement in patients' quality of life, were confirmed in the INVICTUS trial, leading to rapetinib's approval as a fourth-line or higher treatment option for patients with GIST.

Results from the NVICTUS trial establish repetitinib as a treatment option for patients with unresectable or metastatic GIST who have progressed on three or more TKIs, including imatinib, with the exception of patients with GIST harboring PDGFRA exon 18 mutations. Ripetinib had a favorable toxicity profile and improved patient-reported quality of life compared with placebo.

The original drug of Ripetinib has been launched in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of 50mg*30 tablets per box may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens, and there may not yet be domestically produced drugs. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.